These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 32151645)

  • 21. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
    Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
    BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
    Ali SO; Takas T; Nyborg A; Shoemaker K; Kallewaard NL; Chiong R; Dubovsky F; Mallory RM
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial.
    Liebowitz D; Lindbloom JD; Brandl JR; Garg SJ; Tucker SN
    Lancet Infect Dis; 2015 Sep; 15(9):1041-1048. PubMed ID: 26333337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.
    Liebowitz D; Gottlieb K; Kolhatkar NS; Garg SJ; Asher JM; Nazareno J; Kim K; McIlwain DR; Tucker SN
    Lancet Infect Dis; 2020 Apr; 20(4):435-444. PubMed ID: 31978354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of aloin on viral neuraminidase and hemagglutinin-specific T cell immunity in acute influenza.
    Huang CT; Hung CY; Hseih YC; Chang CS; Velu AB; He YC; Huang YL; Chen TA; Chen TC; Lin CY; Lin YC; Shih SR; Dutta A
    Phytomedicine; 2019 Nov; 64():152904. PubMed ID: 31454654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.
    Hung IFN; To KKW; Lee CK; Lee KL; Yan WW; Chan K; Chan WM; Ngai CW; Law KI; Chow FL; Liu R; Lai KY; Lau CCY; Liu SH; Chan KH; Lin CK; Yuen KY
    Chest; 2013 Aug; 144(2):464-473. PubMed ID: 23450336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza H1N1 infection in a patient with psoriatic arthritis in treatment with Adalimumab: a case report.
    Serrato VA; Azevedo VF; Sabatoski V; Gonçalves BP; Machado DM
    Clin Rheumatol; 2013 Mar; 32 Suppl 1(Suppl 1):S21-3. PubMed ID: 20204666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
    Hayden FG; Treanor JJ; Fritz RS; Lobo M; Betts RF; Miller M; Kinnersley N; Mills RG; Ward P; Straus SE
    JAMA; 1999 Oct; 282(13):1240-6. PubMed ID: 10517426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia.
    Lee N; Chan PK; Wong CK; Wong KT; Choi KW; Joynt GM; Lam P; Chan MC; Wong BC; Lui GC; Sin WW; Wong RY; Lam WY; Yeung AC; Leung TF; So HY; Yu AW; Sung JJ; Hui DS
    Antivir Ther; 2011; 16(2):237-47. PubMed ID: 21447873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
    Wang C; Cao B; Liu QQ; Zou ZQ; Liang ZA; Gu L; Dong JP; Liang LR; Li XW; Hu K; He XS; Sun YH; An Y; Yang T; Cao ZX; Guo YM; Wen XM; Wang YG; Liu YL; Jiang LD
    Ann Intern Med; 2011 Aug; 155(4):217-25. PubMed ID: 21844547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
    Song JY; Noh JY; Choi WS; Cheong HJ; Kim WJ
    Expert Rev Anti Infect Ther; 2015; 13(11):1361-72. PubMed ID: 26256778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study.
    Beran J; Šalapová E; Špajdel M;
    BMC Infect Dis; 2016 Nov; 16(1):648. PubMed ID: 27821093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
    Low JG; Lee LS; Ooi EE; Ethirajulu K; Yeo P; Matter A; Connolly JE; Skibinski DA; Saudan P; Bachmann M; Hanson BJ; Lu Q; Maurer-Stroh S; Lim S; Novotny-Diermayr V
    Vaccine; 2014 Sep; 32(39):5041-8. PubMed ID: 25045806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge.
    Fries LF; Dillon SB; Hildreth JE; Karron RA; Funkhouser AW; Friedman CJ; Jones CS; Culleton VG; Clements ML
    J Infect Dis; 1993 Mar; 167(3):593-601. PubMed ID: 8440931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
    Geppe NA; Kondiurina EG; Galustian AN; Pak TE; Bal'tserovich NB; Zhiglinskaia OV; Kamaev AV; Lazareva SG; Laléko SL; Mel'nikova IM; Perminova OA; Sabitov AU
    Antibiot Khimioter; 2014; 59(5-6):6-14. PubMed ID: 25552038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
    Ruangrung K; Suptawiwat O; Maneechotesuwan K; Boonarkart C; Chakritbudsabong W; Assawabhumi J; Bhattarakosol P; Uiprasertkul M; Puthavathana P; Wiriyarat W; Jongkaewwattana A; Auewarakul P
    J Virol; 2016 May; 90(9):4637-4646. PubMed ID: 26912622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.